Dr Vasilios Karavasilis

Tel: 020 3447 9346
Fax: 020 3447 9055
Email: uclh.oncology.sarcoma.admin@nhs.net

University College Hospital

Sarcoma - The London Sarcoma Service

Professional background

Dr Karavasilis was appointed as a Consultant Medical Oncologist at UCLH in 2015 and since then has joint a very active team at the London Sarcoma Service, which in conjunction with the Royal National Orthopaedic Hospital, constitutes one of the largest sarcoma services in Europe. Vasilios is also Assistant Professor of Oncology at Aristotle University of Thessaloniki, Greece and upon recently he has served as a director of the academic medical oncology department there. He has trained partly in Greece and the UK at the Royal Marsden Hospital in London.

Research interests

Dr Karavasilis has a strong interest in clinical and translational research in rare cancers, including sarcomas and he has done his PhD thesis investigated the role of angiogenesis and proteolysis in cancer of unknown primary origin. For almost 20 years, he has significant experience in early clinical trials, pharmacokinetics and pharmacodynamics of novel agents both in Greece and UK.


Use of proteins as biomarkers and their role in carcinogenesis. Zarogoulidis P, Tsakiridis K, Karapantzou C, Lampaki S, Kioumis I, Pitsiou G, Papaiwannou A, Hohenforst-Schmidt W, Huang H, Kesisis G, Karapantzos I, Chlapoutakis S, Korantzis I, Mpakas A, Karavasilis V, Mpoukovinas I, Li Q, Zarogoulidis K. J Cancer. 2015 Jan 1;6(1):9-18. doi: 10.7150/jca.10560. eCollection 2015. Review

Acquired ichthyosis triggered by an osseous hemangiopericytoma: a case report and review of the literature. Patsatsi A, Kyriakou A, Karavasilis V, Tsatsou F, Lazaridis G, Kalabalikis D, Sotiriadis D. Case Rep Dermatol. 2014 Jan 18;6(1):10-5. doi: 10.1159/000358294. eCollection 2014 Jan.

Revisiting bleomycin from pathophysiology to safe clinical use. Froudarakis M, Hatzimichael E, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E. Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100. doi: 10.1016/j.critrevonc.2012.12.003. Epub 2013 Jan 9. Review.

A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. Karavasilis V, Kotoula V, Pentheroudakis G, Televantou D, Lambaki S, Chrisafi S, Bobos M, Fountzilas G. J Neurol. 2013 Jun;260(6):1469-80. doi: 10.1007/s00415-012-6812-z. Epub 2013 Jan 5.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.

Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR. Sarcoma. 2010;2010:264360. doi: 10.1155/2010/264360. Epub 2010 May 20.

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376.

Leiomyosarcoma as a second metachronous malignant neoplasm following colon adenocarcinoma. A case report and review of the literature. Mavrodontidis A, Zalavras C, Skopelitou A, Karavasilis V, Briasoulis E. Sarcoma. 2001;5(1):31-3.

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Karavasilis V, Digue L, Arkenau T, Eaton D, Stapleton S, de Bono J, Judson I, Kaye S. Eur J Cancer. 2008 May;44(7):978-82. doi: 10.1016/j.ejca.2008.02.040. Epub 2008 Mar 24.

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Cancer. 2008 Apr 1;112(7):1585-91.

Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. Briasoulis E, Karavasilis V, Tzamakou E, Piperidou C, Soulti K, Pavlidis N. Anticancer Drugs. 2006 Nov;17(10):1219-22.

Matrix metalloproteinases in carcinoma of unknown primary. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. Cancer. 2005 Nov 15;104(10):2282-7.

Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Cancer Chemother Pharmacol. 2005 Oct;56(4):358-60. Epub 2005 May 10.

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. BMC Cancer. 2005 Mar 3;5:25.

Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Briasoulis E, Karavasilis V, Tzamakou E, Haidou C, Piperidou C, Pavlidis N. Anticancer Drugs. 2002 Jun;13(5):481-9.

Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakou E, Fountzilas G, Rammou D, Kostadima V, Pavlidis N. Ann Oncol. 1999 Jun;10(6):701-6.

GMC/GDC number: 6106585